Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice

Experimental Neurology

Volumn 190, Issue 2, 2004, Pages 515-524

  Zeng, B Y ^a   Heales, S J R ^b   Canevari, L ^b   Rose, S ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

DA receptors; Dopa responsive dystonia; GTP cyclohydrolase deficiency; hph 1 mouse; Neuropeptides

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR D3; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MAZINDOL; MESSENGER RNA; NEUROPEPTIDE; NITRIC OXIDE SYNTHASE; PREPROENDOTHELIN; PREPROTACHYKININ; SPIPERONE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DYSTONIA; ENZYME DEFICIENCY; GENE EXPRESSION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SUBSTANTIA NIGRA;

ANIMALS; AUTORADIOGRAPHY; BRAIN; DISEASE MODELS, ANIMAL; DYSTONIA; ENKEPHALINS; GTP CYCLOHYDROLASE; IN SITU HYBRIDIZATION; MICE; NEUROPEPTIDES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PRESYNAPTIC TERMINALS; PROTEIN PRECURSORS; RECEPTORS, DOPAMINE; RNA, MESSENGER; TACHYKININS; TYROSINE 3-MONOOXYGENASE;

EID: 8644226273     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.08.022     Document Type: Article

References (58)

1. G.M. Alexander, R.J. Schwartzman, J.R. Grothusen, L. Brainard, and S.W. Gordon Changes in brain dopamine receptors in MPTP parkinsonian monkeys following l-dopa treatment Brain Res. 625 1993 276 282
2. O. Bandmann, E.M. Valente, P. Holmans, R.A. Surtees, J.H. Walters, R.A. Wevers, C.D. Marsden, and N.W. Wood Dopa-responsive dystonia: a clinical and molecular genetic study Ann. Neurol. 44 1998 649 656
3. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U. S. A. 94 1997 3363 3367
4. M.P. Brand, S.J. Heales, J.M. Land, and J.B. Clark Tetrahydrobiopterin deficiency and brain nitric oxide synthase in the hph1 mouse J. Inherit. Metab. Dis. 18 1995 33 39
5. M.P. Brand, A. Briddon, J.M. Land, J.B. Clark, and S.J. Heales Neurochemical effects following peripheral administration of tetrahydropterin derivatives to the hph-1 mouse J. Neurochem. 66 1996 1150 1156
6. M.P. Brand, K. Hyland, T. Engle, I. Smith, and S.J. Heales Impairment of the nitric oxide/cyclic GMP pathway in cerebellar slices prepared from the hph-1 mouse Brain Res. 735 1996 169 172
7. D.S. Bredt, C.E. Glatt, P.M. Hwang, M. Fotuhi, T.M. Dawson, and S.H. Snyder Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase Neuron 7 1991 615 624
8. L. Canevari, J.M. Land, J.B. Clark, and S.J. Heales Stimulation of the brain NO/cyclic GMP pathway by peripheral administration of tetrahydrobiopterin in the hph-1 mouse J. Neurochem. 73 1999 2563 2568
9. J.F. Chen, V.J. Aloyo, and B. Weiss Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum Neuroscience 54 1993 669 680
10. C. Chiwakata, B. Brackmann, N. Hunt, M. Davidoff, W. Schulze, and R. Ivell Tachykinin (substance-P) gene expression in Leydig cells of the human and mouse testis Endocrinology 128 1991 2441 2448
11. S.J. Cragg, and S.A. Greenfield Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum J. Neurosci. 17 1997 5738 5746
12. K.M. Dewar, and T.A. Reader Distribution of dopamine D1 and D2 receptors in rabbit cortical areas, hippocampus, and neostriatum in relation to dopamine contents Synapse 4 1989 378 386
13. D. Eidelberg, J.R. Moeller, T. Ishikawa, V. Dhawan, P. Spetsieris, S. Przedborski, and S. Fahn The metabolic topography of idiopathic torsion dystonia Brain 118 1995 1473 1484
14. Y. Furukawa, T.G. Nygaard, M. Gutlich, A.H. Rajput, C. Pifl, L. DiStefano, L.J. Chang, K. Price, M. Shimadzu, O. Hornykiewicz, J.W. Haycock, and S.J. Kish Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia Neurology 53 1999 1032 1041
15. C. Gagnon, P.J. Bedard, and T. Di Paolo Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists Eur. J. Pharmacol. 178 1990 115 120
16. C.R. Gerfen, T.M. Engber, L.C. Mahan, Z. Susel, T.N. Chase, F.J. Monsma Jr., and D.R. Sibley D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 1990 1429 1432
17. W.C. Graham, M.A. Sambrook, and A.R. Crossman Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism Brain Res. 602 1993 290 303
18. A.M. Graybiel The basal ganglia Curr. Biol. 10 2000 R509 R511
19. B. Grima, A. Lamouroux, F. Blanot, N.F. Biguet, and J. Mallet Complete coding sequence of rat tyrosine hydroxylase mRNA Proc. Natl. Acad. Sci. U. S. A. 82 1985 617 621
20. M.J. Heeringa, and E.D. Abercrombie Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release J. Neurochem. 65 1995 192 200
21. M.T. Herrero, S.J. Augood, E.C. Hirsch, F. Javoyagid, M.R. Luquin, Y. Agid, J.A. Obeso, and P.C. Emson Effects of l-DOPA on preproenkephalin and preprotachykinin gene-expression in the MPTP-treated monkey striatum Neuroscience 68 1995 1189 1198
22. C.C. Huang, T.C. Yen, Y.H. Weng, and C.S. Lu Normal dopamine transporter binding in dopa responsive dystonia J. Neurol. 249 2002 1016 1020
23. M.J. Hurley, J. Jolkkonen, C.M. Stubbs, P. Jenner, and C.D. Marsden Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and l-DOPA treatment Brain Res. 709 1996 259 264
24. K. Hyland, R.S. Gunasekera, T. Engle, and L.A. Arnold Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse J. Neurochem. 67 1996 752 759
25. H. Ichinose, T. Ohye, E. Takahashi, N. Seki, T. Hori, M. Segawa, Y. Nomura, K. Endo, H. Tanaka, and S. Tsuji Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene Nat. Genet. 8 1994 236 242
26. I. Irwin, L.E. DeLanney, L.S. Forno, K.T. Finnegan, D.A. Di Monte, and J.W. Langston The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey Brain Res. 531 1990 242 252
27. J.A. Javitch, S.M. Strittmatter, and S.H. Snyder Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography J. Neurosci. 5 1985 1513 1521
28. J. Jolkkonen, P. Jenner, and C.D. Marsden l-DOPA reverses altered gene-expression of substance-P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP Mol. Brain Res. 32 1995 297 307
29. S. Kaufman, G. Kapatos, W.B. Rizzo, J.D. Schulman, L. Tamarkin, and G.R. Van Loon Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin Ann. Neurol. 14 1983 308 315
30. A. Kishore, T.G. Nygaard, R. Fuente-Fernandez, A.B. Naini, M. Schulzer, E. Mak, T.J. Ruth, D.B. Calne, B.J. Snow, and A.J. Stoessl Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography Neurology 50 1998 1028 1032
31. G. Kunig, K.L. Leenders, A. Antonini, P. Vontobel, A. Weindl, and H.M. Meinck D2 receptor binding in dopa-responsive dystonia Ann. Neurol. 44 1998 758 762
32. K.L. Leenders, N. Quinn, R.S. Frackowiak, and C.D. Marsden Brain dopaminergic system studied in patients with dystonia using positron emission tomography Adv. Neurol. 50 1988 243 247
33. S. Magyar-Lehmann, A. Antonini, U. Roelcke, R.P. Maguire, J. Missimer, M. Meyer, and K.L. Leenders Cerebral glucose metabolism in patients with spasmodic torticollis Mov. Disord. 12 1997 704 708
34. C.D. Marsden, and N.P. Quinn The dystonias BMJ 300 1990 139 144
35. J.D. McDonald, R.G. Cotton, I. Jennings, F.D. Ledley, S.L. Woo, and V.C. Bode Biochemical defect of the hph-1 mouse mutant is a deficiency in GTP-cyclohydrolase activity J. Neurochem. 50 1988 655 657
36. M. Morissette, M. Goulet, J.J. Soghomonian, P.J. Blanchet, F. Calon, P.J. Bedard, and T. Di Paolo Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy Mol. Brain Res. 49 1997 55 62
37. A.P. Nisbet, O.J.F. Foster, A. Kingsbury, D.J. Eve, S.E. Daniel, C.D. Marsden, and A.J. Lees Preproenkephalin and preprotachykinin messenger-RNA expression in normal human basal ganglia and in Parkinson's disease Neuroscience 66 1995 361 376
38. T.G. Nygaard, C.D. Marsden, and R.C. Duvoisin Dopa-responsive dystonia Adv. Neurol. 50 1988 377 384
39. M. Otsuka, Y. Ichiya, F. Shima, Y. Kuwabara, M. Sasaki, T. Fukumura, M. Kato, K. Masuda, and I. Goto Increased striatal 18F-dopa uptake and normal glucose metabolism in idiopathic dystonia syndrome J. Neurol. Sci. 111 1992 195 199
40. J.S. Perlmutter, L.W. Tempel, K.J. Black, D. Parkinson, and R.D. Todd MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia Neurology 49 1997 1432 1438
41. L. Pierot, C. Desnos, J. Blin, R. Raisman, D. Scherman, F. Javoy-Agid, M. Ruberg, and Y. Agid D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy J. Neurol. Sci. 86 1988 291 306
42. A.H. Rajput, W.R. Gibb, X.H. Zhong, K.S. Shannak, S. Kish, L.G. Chang, and O. Hornykiewicz Dopa-responsive dystonia: pathological and biochemical observations in a case Ann. Neurol. 35 1994 396 402
43. J.O. Rinne, M. Iivanainen, L. Metsahonkala, L. Vainionpaa, L. Paakkonen, K. Nagren, and H. Helenius Striatal dopaminergic system in dopa-responsive dystonia: a multi-tracer PET study shows increased D2 receptors J. Neural Transm. 111 2004 59 67
44. G.V. Sawle, K.L. Leenders, D.J. Brooks, G. Harwood, A.J. Lees, R.S. Frackowiak, and C.D. Marsden Dopa-responsive dystonia: [18F]dopa positron emission tomography Ann. Neurol. 30 1991 24 30
45. Y. Schmitz, C. Schmauss, and D. Sulzer Altered dopamine release and uptake kinetics in mice lacking D2 receptors J. Neurosci. 22 2002 8002 8009
46. P. Seeman, N.H. Bzowej, H.C. Guan, C. Bergeron, G.P. Reynolds, E.D. Bird, P. Riederer, K. Jellinger, and W.W. Tourtellotte Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases Neuropsychopharmacology 1 1987 5 15
47. M. Shimoji, K. Hirayama, K. Hyland, and G. Kapatos GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice J. Neurochem. 72 1999 757 764
48. B.J. Snow, T.G. Nygaard, H. Takahashi, and D.B. Calne Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism Ann. Neurol. 34 1993 733 738
49. B.C. Tel, B.Y. Zeng, C. Cannizzaro, R.K.B. Pearce, S. Rose, and P. Jenner Alterations in striatal neuropeptid mRNA produced by repeated administration of l-dopa, ropinirole or bromcriptine correlate with dyskinesia induction in MPTP-treated common marmosets Neuroscience 115 2002 1047 1058
50. R.D. Todd, and J.S. Perlmutter Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition Mol. Neurobiol. 16 1998 135 147
51. N. Turjanski, A.J. Lees, and D.J. Brooks In vivo studies on striatal dopamine D1 and D2 site binding in l-dopa-treated Parkinson's disease patients with and without dyskinesias Neurology 49 1997 717 723
52. M. Wassef, A. Berod, and C. Sotelo Dopaminergic dendrites in the pars reticulata of the rat substantia nigra and their striatal input. Combined immunocytochemical localization of tyrosine hydroxylase and anterograde degeneration Neuroscience 6 1981 2125 2139
53. T. Wichmann, and M.R. DeLong Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder Ann. N. Y. Acad. Sci. 991 2003 199 213
54. B.Y. Zeng, J. Jolkkonen, P. Jenner, and C.D. Marsden Chronic l-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine- lesioned rat Neuroscience 66 1995 19 28
55. B.Y. Zeng, R.K. Pearce, G.M. MacKenzie, and P. Jenner Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA Eur. J. Neurosci. 12 2000 1096 1104
56. B.Y. Zeng, R.K. Pearce, G.M. MacKenzie, and P. Jenner Chronic high dose l-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study J. Neural Transm. 108 2001 925 941
57. Q.Y. Zhou, D.K. Grandy, L. Thambi, J.A. Kushner, H.H. Van Tol, R. Cone, D. Pribnow, J. Salon, J.R. Bunzow, and O. Civelli Cloning and expression of human and rat D1 dopamine receptors Nature 347 1990 76 80
58. G. Zurawski, M. Benedik, B.J. Kamb, J.S. Abrams, S.M. Zurawski, and F.D. Lee Activation of mouse T-helper cells induces abundant preproenkephalin mRNA synthesis Science 232 1986 772 775